Upjohn Drug Patent Portfolio

Upjohn owns 9 orange book drugs protected by 63 US patents with Detrol having the least patent protection, holding only 1 patent. And Inspra with maximum patent protection, holding 16 patents. Given below is the list of Upjohn's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10022447 Solid pharmaceutical compositions containing pregabalin 02 May, 2027
Active
US8945620 Solid pharmaceutical compositions containing pregabalin 02 May, 2027
Active
US9144559 Solid pharmaceutical compositions containing pregabalin 02 May, 2027
Active
US10022447 Solid pharmaceutical compositions containing pregabalin 02 Nov, 2026
Active
US8945620 Solid pharmaceutical compositions containing pregabalin 02 Nov, 2026
Active
US9144559 Solid pharmaceutical compositions containing pregabalin 02 Nov, 2026
Active
US6863902 Immediate release eplerenone compositions 10 Oct, 2020 Expired
US6410054 Immediate release eplerenone compositions 08 Jun, 2020 Expired
US6495165 Eplerenone compositions having improved bioavailability 08 Jun, 2020 Expired
US6534093 Immediate release eplerenone compositions 08 Jun, 2020 Expired
US6558707 Immediate release eplerenone compositions 08 Jun, 2020 Expired
US7157101 Micronized eplerenone compositions 08 Jun, 2020 Expired
US6630162 Pharmaceutical formulation and its use 11 May, 2020 Expired
US6911217 Controlled release bead, a method of producing the same and multiple unit formulation comprising it 11 May, 2020 Expired
US6410524 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease 05 May, 2020 Expired
US6747020 Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor 05 May, 2020 Expired
US6863902 Immediate release eplerenone compositions 10 Apr, 2020 Expired
US6770295 Therapeutic formulation for administering tolterodine with controlled release 26 Feb, 2020 Expired
US6410054 Immediate release eplerenone compositions 08 Dec, 2019 Expired
US6495165 Eplerenone compositions having improved bioavailability 08 Dec, 2019 Expired
US6534093 Immediate release eplerenone compositions 08 Dec, 2019 Expired
US6558707 Immediate release eplerenone compositions 08 Dec, 2019 Expired
US7157101 Micronized eplerenone compositions 08 Dec, 2019 Expired
US6630162 Pharmaceutical formulation and its use 11 Nov, 2019 Expired
US6911217 Controlled release bead, a method of producing the same and multiple unit formulation comprising it 11 Nov, 2019 Expired
US6410524 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease 05 Nov, 2019 Expired
US6747020 Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor 05 Nov, 2019 Expired
US6770295 Therapeutic formulation for administering tolterodine with controlled release 26 Aug, 2019 Expired
US6001876 Isobutylgaba and its derivatives for the treatment of pain 30 Jun, 2019 Expired
US6197819 Gamma amino butyric acid analogs and optical isomers 30 Jun, 2019 Expired
USRE41920 Isobutylgaba and its derivatives for the treatment of pain 30 Jun, 2019 Expired
US6001876 Isobutylgaba and its derivatives for the treatment of pain 30 Dec, 2018 Expired
US6197819 Gamma amino butyric acid analogs and optical isomers 30 Dec, 2018 Expired
USRE41920 Isobutylgaba and its derivatives for the treatment of pain 30 Dec, 2018 Expired
US6274171 Extended release formulation of venlafaxine hydrochloride 20 Sep, 2017 Expired
US6403120 Extended release formulation of venlafaxine hydrochloride 20 Sep, 2017 Expired
US6419958 Extended release formulation of venlafaxine hydrochloride 20 Sep, 2017 Expired
US6110940 Salts of an anti-migraine indole derivative 29 Aug, 2017 Expired
US6274171 Extended release formulation of venlafaxine hydrochloride 20 Mar, 2017 Expired
US6403120 Extended release formulation of venlafaxine hydrochloride 20 Mar, 2017 Expired
US6419958 Extended release formulation of venlafaxine hydrochloride 20 Mar, 2017 Expired
US5969156 Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) 08 Jan, 2017 Expired
US5545644 Indole derivatives 26 Dec, 2016 Expired
US5969156 Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) 08 Jul, 2016 Expired
US5760068 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation 02 Dec, 2015 Expired
USRE44048 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder 02 Dec, 2015 Expired
US5760068 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation 02 Jun, 2015 Expired
USRE44048 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder 02 Jun, 2015 Expired
US5686104 Stable oral CI-981 formulation and process of preparing same 11 May, 2015 Expired
US5686104 Stable oral CI-981 formulation and process of preparing same 11 Nov, 2014 Expired
US5466823 Substituted pyrazolyl benzenesulfonamides 30 May, 2014 Expired
US5563165 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation 30 May, 2014 Expired
US5916923 Venlafaxine for the treatment of generalized anxiety disorder 28 Dec, 2013 Expired
US6444708 Treatment using venlafaxine 28 Dec, 2013 Expired
US5466823 Substituted pyrazolyl benzenesulfonamides 30 Nov, 2013 Expired
US5563165 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation 30 Nov, 2013 Expired
US5563175 GABA and L-glutamic acid analogs for antiseizure treatment 08 Oct, 2013 Expired
US6126971 Stable oral CI-981 formulation and process for preparing same 19 Jul, 2013 Expired
US5916923 Venlafaxine for the treatment of generalized anxiety disorder 28 Jun, 2013 Expired
US6310101 Treatments using venlafaxine 28 Jun, 2013 Expired
US6444708 Treatment using venlafaxine 28 Jun, 2013 Expired
US6126971 Stable oral CI-981 formulation and process for preparing same 19 Jan, 2013 Expired
US5382600 3,3-diphenylpropylamines and pharmaceutical compositions thereof 25 Sep, 2012 Expired


Given below is the list of recent legal activities going on the following drug patents of Upjohn.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 21 Mar, 2023 US9144559
Payment of Maintenance Fee, 8th Year, Large Entity 26 Jul, 2022 US8945620
Payment of Maintenance Fee, 4th Year, Large Entity 04 Jan, 2022 US10022447
Email Notification 29 Jul, 2021 US9144559
Email Notification 29 Jul, 2021 US8945620
Change in Power of Attorney (May Include Associate POA) 29 Jul, 2021 US9144559
Change in Power of Attorney (May Include Associate POA) 29 Jul, 2021 US8945620
Correspondence Address Change 27 Jul, 2021 US8945620
Correspondence Address Change 27 Jul, 2021 US9144559
Change in Power of Attorney (May Include Associate POA) 14 Jul, 2021 US10022447
Email Notification 14 Jul, 2021 US10022447
Correspondence Address Change 13 Jul, 2021 US10022447
Payment of Maintenance Fee, 4th Year, Large Entity 14 Feb, 2019 US9144559
Patent Issue Date Used in PTA Calculation 17 Jul, 2018 US10022447
Recordation of Patent Grant Mailed 17 Jul, 2018 US10022447


Upjohn's Drug Patent Litigations

Upjohn's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 29, 1996, against patent number US6197819. The petitioner , challenged the validity of this patent, with SILVERMAN et al as the respondent. Click below to track the latest information on how companies are challenging Upjohn's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US6197819 October, 1996 Decision
(10 Jul, 1997)
SILVERMAN et al


Upjohn Drug Patents' Oppositions Filed in EPO

Upjohn drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 21, 2014, by Strawman Limited. This opposition was filed on patent number EP06809154A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP06809154A Oct, 2014 STRAWMAN LIMITED Opposition rejected


Upjohn's Family Patents

Upjohn drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 28.3% of its total global patent coverage. 12 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Upjohn Drug List

Given below is the complete list of Upjohn's drugs and the patents protecting them.


1. Celebrex

Celebrex is protected by 8 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5760068
(Pediatric)
Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation 02 Dec, 2015
(8 years ago)
Expired
USRE44048
(Pediatric)
4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder 02 Dec, 2015
(8 years ago)
Expired
US5760068 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation 02 Jun, 2015
(9 years ago)
Expired
USRE44048 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder 02 Jun, 2015
(9 years ago)
Expired
US5466823
(Pediatric)
Substituted pyrazolyl benzenesulfonamides 30 May, 2014
(10 years ago)
Expired
US5563165
(Pediatric)
Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation 30 May, 2014
(10 years ago)
Expired
US5466823 Substituted pyrazolyl benzenesulfonamides 30 Nov, 2013
(10 years ago)
Expired
US5563165 Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation 30 Nov, 2013
(10 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Celebrex's drug page


2. Detrol

Detrol is protected by 1 patent, which has expired already. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5382600
(Pediatric)
3,3-diphenylpropylamines and pharmaceutical compositions thereof 25 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Detrol's drug page


3. Detrol La

Detrol La is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6630162
(Pediatric)
Pharmaceutical formulation and its use 11 May, 2020
(4 years ago)
Expired
US6911217
(Pediatric)
Controlled release bead, a method of producing the same and multiple unit formulation comprising it 11 May, 2020
(4 years ago)
Expired
US6770295
(Pediatric)
Therapeutic formulation for administering tolterodine with controlled release 26 Feb, 2020
(4 years ago)
Expired
US6630162 Pharmaceutical formulation and its use 11 Nov, 2019
(4 years ago)
Expired
US6911217 Controlled release bead, a method of producing the same and multiple unit formulation comprising it 11 Nov, 2019
(4 years ago)
Expired
US6770295 Therapeutic formulation for administering tolterodine with controlled release 26 Aug, 2019
(5 years ago)
Expired
US5382600
(Pediatric)
3,3-diphenylpropylamines and pharmaceutical compositions thereof 25 Sep, 2012
(12 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Detrol La's drug page


4. Effexor Xr

Effexor Xr is protected by 11 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6274171
(Pediatric)
Extended release formulation of venlafaxine hydrochloride 20 Sep, 2017
(7 years ago)
Expired
US6403120
(Pediatric)
Extended release formulation of venlafaxine hydrochloride 20 Sep, 2017
(7 years ago)
Expired
US6419958
(Pediatric)
Extended release formulation of venlafaxine hydrochloride 20 Sep, 2017
(7 years ago)
Expired
US6274171 Extended release formulation of venlafaxine hydrochloride 20 Mar, 2017
(7 years ago)
Expired
US6403120 Extended release formulation of venlafaxine hydrochloride 20 Mar, 2017
(7 years ago)
Expired
US6419958 Extended release formulation of venlafaxine hydrochloride 20 Mar, 2017
(7 years ago)
Expired
US5916923
(Pediatric)
Venlafaxine for the treatment of generalized anxiety disorder 28 Dec, 2013
(10 years ago)
Expired
US6444708
(Pediatric)
Treatment using venlafaxine 28 Dec, 2013
(10 years ago)
Expired
US5916923 Venlafaxine for the treatment of generalized anxiety disorder 28 Jun, 2013
(11 years ago)
Expired
US6310101 Treatments using venlafaxine 28 Jun, 2013
(11 years ago)
Expired
US6444708 Treatment using venlafaxine 28 Jun, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Effexor Xr's drug page


5. Inspra

Inspra is protected by 16 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6863902
(Pediatric)
Immediate release eplerenone compositions 10 Oct, 2020
(4 years ago)
Expired
US6410054
(Pediatric)
Immediate release eplerenone compositions 08 Jun, 2020
(4 years ago)
Expired
US6495165
(Pediatric)
Eplerenone compositions having improved bioavailability 08 Jun, 2020
(4 years ago)
Expired
US6534093
(Pediatric)
Immediate release eplerenone compositions 08 Jun, 2020
(4 years ago)
Expired
US6558707
(Pediatric)
Immediate release eplerenone compositions 08 Jun, 2020
(4 years ago)
Expired
US7157101
(Pediatric)
Micronized eplerenone compositions 08 Jun, 2020
(4 years ago)
Expired
US6410524
(Pediatric)
Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease 05 May, 2020
(4 years ago)
Expired
US6747020
(Pediatric)
Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor 05 May, 2020
(4 years ago)
Expired
US6863902 Immediate release eplerenone compositions 10 Apr, 2020
(4 years ago)
Expired
US6410054 Immediate release eplerenone compositions 08 Dec, 2019
(4 years ago)
Expired
US6495165 Eplerenone compositions having improved bioavailability 08 Dec, 2019
(4 years ago)
Expired
US6534093 Immediate release eplerenone compositions 08 Dec, 2019
(4 years ago)
Expired
US6558707 Immediate release eplerenone compositions 08 Dec, 2019
(4 years ago)
Expired
US7157101 Micronized eplerenone compositions 08 Dec, 2019
(4 years ago)
Expired
US6410524 Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease 05 Nov, 2019
(4 years ago)
Expired
US6747020 Methods of treating heart failure and hypertension using combinations of eplerenone and an angiotensin converting enzyme inhibitor 05 Nov, 2019
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Inspra's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

6. Lipitor

Lipitor is protected by 6 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US5969156
(Pediatric)
Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) 08 Jan, 2017
(7 years ago)
Expired
US5969156 Crystalline [R- (R*,R*)]-2-(4-Dfluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)- 3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) 08 Jul, 2016
(8 years ago)
Expired
US5686104
(Pediatric)
Stable oral CI-981 formulation and process of preparing same 11 May, 2015
(9 years ago)
Expired
US5686104 Stable oral CI-981 formulation and process of preparing same 11 Nov, 2014
(9 years ago)
Expired
US6126971
(Pediatric)
Stable oral CI-981 formulation and process for preparing same 19 Jul, 2013
(11 years ago)
Expired
US6126971 Stable oral CI-981 formulation and process for preparing same 19 Jan, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lipitor's drug page


7. Lyrica

Lyrica is protected by 7 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6001876
(Pediatric)
Isobutylgaba and its derivatives for the treatment of pain 30 Jun, 2019
(5 years ago)
Expired
US6197819
(Pediatric)
Gamma amino butyric acid analogs and optical isomers 30 Jun, 2019
(5 years ago)
Expired
USRE41920
(Pediatric)
Isobutylgaba and its derivatives for the treatment of pain 30 Jun, 2019
(5 years ago)
Expired
US6001876 Isobutylgaba and its derivatives for the treatment of pain 30 Dec, 2018
(5 years ago)
Expired
US6197819 Gamma amino butyric acid analogs and optical isomers 30 Dec, 2018
(5 years ago)
Expired
USRE41920 Isobutylgaba and its derivatives for the treatment of pain 30 Dec, 2018
(5 years ago)
Expired
US5563175 GABA and L-glutamic acid analogs for antiseizure treatment 08 Oct, 2013
(11 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lyrica's drug page


8. Lyrica Cr

Lyrica Cr is protected by 10 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10022447
(Pediatric)
Solid pharmaceutical compositions containing pregabalin 02 May, 2027
(2 years from now)
Active
US8945620
(Pediatric)
Solid pharmaceutical compositions containing pregabalin 02 May, 2027
(2 years from now)
Active
US9144559
(Pediatric)
Solid pharmaceutical compositions containing pregabalin 02 May, 2027
(2 years from now)
Active
US10022447 Solid pharmaceutical compositions containing pregabalin 02 Nov, 2026
(2 years from now)
Active
US8945620 Solid pharmaceutical compositions containing pregabalin 02 Nov, 2026
(2 years from now)
Active
US9144559 Solid pharmaceutical compositions containing pregabalin 02 Nov, 2026
(2 years from now)
Active
US6197819
(Pediatric)
Gamma amino butyric acid analogs and optical isomers 30 Jun, 2019
(5 years ago)
Expired
USRE41920
(Pediatric)
Isobutylgaba and its derivatives for the treatment of pain 30 Jun, 2019
(5 years ago)
Expired
US6197819 Gamma amino butyric acid analogs and optical isomers 30 Dec, 2018
(5 years ago)
Expired
USRE41920 Isobutylgaba and its derivatives for the treatment of pain 30 Dec, 2018
(5 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lyrica Cr's drug page


9. Relpax

Relpax is protected by 2 patents, out of which all have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US6110940 Salts of an anti-migraine indole derivative 29 Aug, 2017
(7 years ago)
Expired
US5545644 Indole derivatives 26 Dec, 2016
(7 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Relpax's drug page